Conditions: Platinum-sensitive Relapsed Epithelial Ovarian Cancer; Platinum-sensitive Relapsed Fallopian Tube Cancer; Platinum-sensitive Relapsed Primary Peritoneal Cancer
Interventions: Drug: Torvutatug samrotecan; Drug: Bevacizumab
Sponsors: AstraZeneca; GOG Foundation; European Network of Gynaecological Oncological Trial Groups (ENGOT); Ventana Medical Systems, Inc
Not yet **RECRUITING NOW**
Interventions: Drug: Torvutatug samrotecan; Drug: Bevacizumab
Sponsors: AstraZeneca; GOG Foundation; European Network of Gynaecological Oncological Trial Groups (ENGOT); Ventana Medical Systems, Inc
Not yet **RECRUITING NOW**
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
